dd-MVAC as neoadjuvant chemotherapy for muscle-invasive bladder cancer: a single-center study
Authors:
- Tatiana E. TikhomirovaTTTatiana E. Tikhomirova
- A. Yu. AnokhinAAA. Yu. Anokhin
- E. R. IsraelyanEIE. R. Israelyan
- А. N. LudАLА. N. Lud
- S. L. GutorovSGS. L. Gutorov
- N. L. VashakmadzeNVN. L. Vashakmadze
- G. A. ArakelyanGAG. A. Arakelyan
- A. V. KlimovAKA. V. Klimov
- A. A. RumyantsevARA. A. Rumyantsev
- V. B. MatveevVMV. B. Matveev
Open Access
- 27 February 2026
- journal article
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (4) , 88-96
Abstract
Aim. To evaluate the efficacy, safety, and feasibility of dd-MVAC (methotrexate, vinblastine, doxorubicin, cyclophosphamide) chemotherapy in real-world clinical practice. Materials and methods. Patients were enrolled between September 2022 and May 2025. They were scheduled to receive six cycles of neoadjuvant dd-MVAC chemotherapy, supported by granulocyte colony-stimulating factor from day 4 to day 9 of each cycle, repeated every two weeks. Eligible patients had urothelial bladder cancer staged as cT2–4a, N0–3, M0, with creatinine clearance of ≥50 mL/min. The primary endpoint was the pathological complete response (pCR) rate. Secondary endpoints included toxicity, the number of treatment cycles completed, and pathological response. Results. The study included 40 patients. Of these, 87 % (n = 35) completed six cycles of dd-MVAC, while 8 % (n = 3) and 5 % (n = 2) completed five and four cycles, respectively. Full protocol drug doses were administered to 57 % of patients (n = 23), while a 15 % dose reduction was required in 43 % (n = 17). The majority of these dose reductions (59 %, n = 10) were implemented after the fifth cycle. The most frequent grade 3 adverse events (per Common Terminology Criteria for Adverse Events (CTCAE) v.5.0) were hematological: neutropenia in 40 % (n = 16), anemia in 10 % (n = 4), and thrombocytopenia in 10 % (n = 4). One fatal case of febrile neutropenia occurred. The most common grade 1–2 adverse event was asthenia reported in 80 % (n = 32) of patients. Surgical treatment was performed in 80 % (n = 32) of the cohort. Cystectomy was conducted in 91 % (n = 29) of these surgical patients, while organ-preserving surgery was performed in 9 % (n = 3). A complete pathological response (ypT0pN0) was achieved in 53 % (n = 17) of surgically treated patients, and downstaging to ypT3pN0 was observed in 9 % (n = 3). Disease stabilization was reported in the remaining 38 % (n = 12). No significant decline in renal function was observed; median glomerular filtration rate was 80.4 mL/min/1.73 m2 pre-treatment and 89.1 mL/min/1.73 m2 post-treatment. Conclusion. The dd-MVAC regimen is an effective and feasible neoadjuvant therapy for muscle-invasive bladder cancer, enabling the majority of patients to complete the full preoperative course of chemotherapy.Keywords
This publication has 5 references indexed in Scilit:
- Global Trends in the Incidence, Mortality, and Risk-attributable Deaths for Prostate, Bladder, and Kidney Cancers: A Systematic Analysis from the Global Burden of Disease Study 2021European Urology Oncology, 2025
- Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 studyThe Lancet Oncology, 2023
- Implications for Efficacy and Safety of Total Dose and Dose-Intensity of Neoadjuvant Gemcitabine-Cisplatin in Muscle-Invasive Bladder Cancer: Three-Week Versus Four-Week RegimenBladder Cancer, 2021
- The Impact of Lymphadenectomy and Lymph Node Metastasis on the Outcomes of Radical Cystectomy for Bladder CancerEuropean Urology, 2009
- Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient DataEuropean Urology, 2005